Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
265.86
-6.19 (-2.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
53
54
Next >
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
April 30, 2024
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
April 24, 2024
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus...
Via
Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
April 23, 2024
These two pharma stocks have followed distinct paths of late. Which is the better investment?
Via
The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
April 23, 2024
This Vanguard growth fund is home to some of the world's most innovative companies.
Via
The Motley Fool
How Is The Market Feeling About Amgen?
April 19, 2024
Via
Benzinga
Looking At Amgen's Recent Unusual Options Activity
April 12, 2024
Via
Benzinga
Is Amgen Stock a Buy?
April 11, 2024
Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.
Via
The Motley Fool
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
April 19, 2024
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns.
Via
InvestorPlace
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300...
Via
Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
April 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
April 17, 2024
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
Via
InvestorPlace
Exposures
Product Safety
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
April 17, 2024
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
7 Analysts Have This To Say About Amgen
April 03, 2024
Via
Benzinga
Amgen Unusual Options Activity For April 02
April 02, 2024
Via
Benzinga
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
April 17, 2024
Amgen's shares have come under pressure this year, making it a compelling bargain buy.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
April 17, 2024
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.
Via
The Motley Fool
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
April 16, 2024
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now.
Via
InvestorPlace
3 Stocks to Buy Low Today With High Hopes for Tomorrow
April 15, 2024
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
Via
InvestorPlace
Amgen, Shell And More On CNBC's 'Final Trades'
April 15, 2024
On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Shell plc (NYSE: SHEL) has 12% free
Via
Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
April 09, 2024
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.
Via
InvestorPlace
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
April 09, 2024
These high-growth biotech stocks are certainly worth considering for investors looking for market-beating returns in the long-term.
Via
InvestorPlace
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
April 07, 2024
Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April.
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
2 Biotech Stocks to Buy Hand Over Fist in April
April 06, 2024
These drugmakers have made important moves over the past year.
Via
The Motley Fool
3 Stocks to Consider Adding to Your Retirement Portfolio in April
April 05, 2024
Use the recent short-term weakness from these powerhouse companies' stocks to your advantage.
Via
The Motley Fool
Topics
Retirement
Exposures
Pension
Is Amgen The Rare Biotech With A Safe Dividend?
April 03, 2024
Amgen pays a $2.25 per share quarterly dividend, which comes out to a 3.3% yield. Biotech can be notoriously volatile, though, so can investors count on receiving the same dividend quarter after...
Via
Talk Markets
Biotech Sector Nears Breakout: Will it Outperform in Q2?
April 03, 2024
The Biotech sector ETF is consolidating in its upper range, indicating a potential sector breakout despite modest year-to-date gains
Via
MarketBeat
Topics
ETFs
5 Healthcare Stocks to Buy for 2024
April 02, 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Redditors Identify 'Best Undervalued Stocks' For 2024
April 01, 2024
Savvy investors at Reddit discuss undervalued stocks for potential growth. Top picks include META, Google, Starbucks, Verizon, and others, with varied perspectives on their potential.
Via
Benzinga
Amgen's Diversified Portfolio To Drive Long-Term Growth, Though Uncertainties Loom, Analyst Says
March 28, 2024
Raymond James resumes coverage of Amgen highlighting its diversified portfolio and strong presence across therapeutic areas for sustainable long-term growth. Innovative pipeline in oncology, rare...
Via
Benzinga
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
53
54
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.